Patent
Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
1. A composition comprising:
a LukA polypeptide analog, wherein said analog comprises the amino acid sequence of amino acid residues 28-341 of SEQ ID NO: 2, and does not comprise the amino acid sequence of amino acid residues 342-351 of SEQ ID NO: 2, wherein said LukA polypeptide analog is non-cytotoxic when combined with a LukB polypeptide comprising the amino acid sequence of amino acid residues 30-339 of SEQ ID NO: 27.
2. The composition of claim 1 further comprising a LukB polypeptide comprising the amino acid sequence of amino acid residues 30-339 of SEQ ID NO: 27.
3. The composition of claim 1 further comprising a pharmaceutically acceptable carrier.